source
- Ultragenyx sells second priority review voucher as Biomea shares tumble after oral GLP-1 dataUltragenyx Pharmaceutical, a commercial-stage rare disease company, completed its second sale of a priority review voucher this month. The voucher sale reflects the company's strategy of monetizin…
- Vir Biotechnology signs $65M upfront deal with Gilead for solid tumor T-cell engagerVir Biotechnology announced a new collaboration with Gilead Sciences focused on a solid tumor T-cell engager. Under the agreement, Gilead will provide an upfront payment of $65 million and up to $…